Drug-carrier interactions in dry powder inhaler formulations employing the Andersen cascade

Drug-carrier interactions in dry powder inhaler formulations working with the Andersen cascade impactor, X-ray microanalysis and time of flight aerosol beam spectrometry (TOFABS). Chem Pharm Bull 2000, 48:167?74. 35. Scalia S, Salama R, Young P, Traini D: Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. J Microencap 2012, 29:225?33.Daman et al. DARU Journal of Pharmaceutical Sciences 2014, 22:50 http://darujps/content/22/1/Page 9 of36. Yu J, Chien YW: Pulmonary drug delivery: physiologic and mechanistic elements. Crit Rev Ther Drug Carrier Syst 1997, 14:395?53. 37. Bosquillon C, Lombry C, Preat V, Vanbever R: Comparison of particle sizing methods inside the case of inhalation dry powders. J Pharm Sci 2001, 90:2032?041. 38. Zeng XM, Martin GP, Marriott C: Particulate Interactions in Dry Powder Formulation for Inhalation. London: Taylor Francis; 2000.doi:10.1186/2008-2231-22-50 Cite this short article as: Daman et al.: Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying approach. DARU Journal of Pharmaceutical Sciences 2014 22:50.Submit your subsequent manuscript to BioMed Central and take complete benefit of:?Easy on line submission ?Thorough peer evaluation ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Analysis which can be freely accessible for redistributionSubmit your manuscript at biomedcentral/submit
ONCOLOGY LETTERS 7: 771-777,Suppression effect of recombinant adenovirus vector containing hIL24 on Hep2 laryngeal carcinoma cellsXUEMEI CHEN1, DI LIU2,3, JUNFU WANG2, QINGHONG SU2, PENG ZHOU2, JINSHENG LIU2, MENG LUAN2 and XIAOQUN XUDepartment of Otolaryngology, The Second Affiliated Hospital of Shandong University, Jinan, Shandong 250033; 2 Institute of Fundamental Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062; three Health-related Laboratory in the People’s Hospital of Tengzhou, Tengzhou, Shandong 277500, P.1H-Imidazole-2-carbaldehyde web R. China Received June 7, 2013; Accepted December 24, 2013 DOI: 10.3892/ol.2014.Abstract. The melanoma differentiation-associated gene-7 [MDA-7; renamed interleukin (IL)-24] was isolated from human melanoma cells induced to terminally differentiate by treatment with interferon and mezerein.5-Methyl-1H-indazol-4-ol supplier MDA-7/IL-24 functions as a multimodality anticancer agent, possessing proapoptotic, antiangiogenic and immunostimulatory properties.PMID:28739548 All these attributes make MDA-7/IL-24 a perfect candidate for cancer gene therapy. Inside the present study, the human MDA-7/IL-24 gene was transfected in to the human laryngeal cancer Hep-2 cell line and human umbilical vein endothelial cells (HUVECs) with a replication-incompetent adenovirus vector. Reverse transcription polymerase chain reaction and western blot evaluation confirmed that the Ad-hIL-24 was expressed in the two cells. The expression with the antiapoptotic gene, Bcl2, was considerably decreased and also the IL24 receptor was markedly expressed in Hep-2 cells following infection with Ad-hIL-24, but not in HUVECs. Also, the expression of your proapoptotic gene, Bax, was induced as well as the expression of caspase-3 was elevated within the Hep-2 cells and HUVECs. Methyl thiazolyl tetrazolium assay indicated that Ad-hIL-24 might induce development suppression in Hep-2 cells but not in HUVECs. In conclusion, Ad-hIL-24 selectively inhibits proliferation and induces apoptosis in Hep-2 cells. No visible damage was located in HUVECs. Thus, the result.